Medical News

[ Hypoallergenic Baby Formula Claims Challenged ]

Hypoallergenic Baby Formula Claims Challenged

Despite the formula being recommended in public health guidelines set out by the Australasian Society of Clinical Immunology and Allergy, the new study, published online in the Journal of Allergy and Clinical Immunology, found there was no benefit in using hypoallergenic (partially hydrolysed whey) formula to prevent allergies in high-risk infants up to seven years of age, compared to a conventional cow's milk based formula. The trial, which is one the largest to test the effect of hypoallergenic baby formula, involved 620 infants and assessed whether using the formula decreased the risk of allergy in later life. Infants in the study were given either hypoallergenic, cow's milk or soy formula after the cessation of breastfeeding. Allergy testing was undertaken at six, 12 and 24 months and children were followed up again at six or seven years of age.

Vitamin D Insufficiency Prevalent Among Psoriatic Arthritis Suffers

New research reports a high prevalence of vitamin D insufficiency and deficiency among patients with psoriatic arthritis. Seasonal variation in vitamin D levels was not observed in patients in southern or northern locations. The findings published in Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), also show no association between disease activity and vitamin D level. Psoriasis is a common chronic skin disorder, likely caused by an autoimmune response, and is characterized by red scaly patches on the surface of the skin. When accompanied by inflammatory arthritis the condition is known as psoriatic arthritis (PsA) - a disease gaining public attention with the recent diagnosis of professional golfer, Phil Mickelson. Studies suggest that psoriasis occurs in up to 3% of the world population and roughly one third of these patients have PsA with prevalence estimates ranging from 6% to 42%.

Anacor Pharmaceuticals Announces Positive Preliminary Results From Phase 2b Trial Of AN2728 For Psoriasis

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today preliminary results from its Phase 2b trial of AN2728 for the treatment of mild-to-moderate plaque-type psoriasis. The trial enrolled 68 subjects randomized in a 2:1 ratio, AN2728 to vehicle. Subjects treated with AN2728 showed improvement over vehicle at each of the recorded timepoints during the 12-week study period with peak efficacy of 26% occurring after six weeks of treatment with AN2728. This Phase 2b trial, while not powered to demonstrate statistical significance, was conducted under anticipated Phase 3 conditions to inform the design and conduct of fully-powered Phase 3 trials. The trial was designed to provide preliminary indications of efficacy and local tolerability and systemic safety when treating all or nearly all of the plaques on each subject.

Certain Drugs Lower Risk Of Diabetes For Patients With Rheumatoid Arthritis Or Psoriasis

In a study that included nearly 14, 000 patients with rheumatoid arthritis or psoriasis, the use of certain disease-modifying antirheumatic drugs was found to lower the risk of diabetes, according to a study in the June 22/29 issue of JAMA. Two common systemic inflammatory conditions, rheumatoid arthritis (RA) and psoriasis, predispose patients to insulin resistance and may place patients at risk for diabetes mellitus (DM). The treatment of psoriasis and RA includes disease-modifying antirheumatic drugs (DMARDs) such as tumor necrosis factor (TNF) inhibitors, which are directed against the inflammatory response, according to background information in the article. The relationship between these conditions and DM suggests that systemic immunosuppression may also reduce the risk for DM.

PsoriasisDX Genetic Test For Psoriatic Arthritis Now Available In Europe As A CE Marked In Vitro Diagnostic Medical Device

Molecular dermatology research and development innovator DermaGenoma, Inc. today announced that the PsoriasisDX Genetic Test for Psoriatic Arthritis (PsA) is now available as a CE Marked product under the European In Vitro Diagnostic Directive. CE Marking is required for certain product groups to indicate conformity with the essential requirements set out in European Directives. The PsoriasisDX Genetic Test for Psoriatic Arthritis complies with the essential requirements of the European IVD Directive. The PsoriasisDX Genetic Test helps identify those at high risk for developing Psoriatic Arthritis before they experience arthritic symptoms, providing the opportunity to lessen joint damage through early medical intervention. "We are excited to extend this revolutionary genetics testing breakthrough to dermatologists in Europe, " says Andy Goren, CEO of DermaGenoma, Inc.

Fast: [10]

Medical News © Nanda
Designer Damodar